Short Interest in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Decreases By 57.4%
by Doug Wharley · The Cerbat GemNeuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) saw a large drop in short interest during the month of May. As of May 15th, there was short interest totaling 19,598 shares, a drop of 57.4% from the April 30th total of 46,010 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average trading volume of 28,089 shares, the short-interest ratio is currently 0.7 days.
Neuphoria Therapeutics Trading Down 0.9%
NASDAQ NEUP traded down $0.05 on Friday, hitting $5.31. 20,300 shares of the company’s stock traded hands, compared to its average volume of 43,591. The firm’s 50-day moving average price is $4.84 and its two-hundred day moving average price is $4.44. The firm has a market capitalization of $28.67 million, a PE ratio of -0.48 and a beta of 0.72. Neuphoria Therapeutics has a 1-year low of $3.64 and a 1-year high of $21.40.
Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.47. On average, research analysts anticipate that Neuphoria Therapeutics will post -4.07 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts have commented on the company. HC Wainwright cut Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Zacks Research raised Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Neuphoria Therapeutics presently has an average rating of “Hold” and an average target price of $21.00.
Read Our Latest Report on Neuphoria Therapeutics
Institutional Investors Weigh In On Neuphoria Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC acquired a new position in shares of Neuphoria Therapeutics in the 4th quarter valued at about $43,000. XTX Topco Ltd acquired a new stake in Neuphoria Therapeutics during the fourth quarter worth about $47,000. Persistent Asset Partners Ltd raised its position in Neuphoria Therapeutics by 173.1% during the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after acquiring an additional 8,495 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in Neuphoria Therapeutics in the fourth quarter valued at approximately $54,000. Finally, Bridgeway Capital Management LLC acquired a new position in Neuphoria Therapeutics in the fourth quarter valued at approximately $57,000. 15.90% of the stock is owned by institutional investors and hedge funds.
Neuphoria Therapeutics Company Profile
Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.